Development and Validation of the Children's Medication Self-Efficacy Scale

Aims: This study aims to develop a tool to assess medication self-efficacy in children and validate the reliability and validity of the Children's Medication Self-Efficacy Scale (CMSES).

Methods: Based on Bandura's theory of self-efficacy and expert recommendations, four items were developed for the scale. Data were collected from 2,258 Chinese children between May and November 2023. Exploratory factor analysis was performed to determine the scale's structure, followed by confirmatory factor analysis to validate it. Both convergent and discriminant validity were assessed. The internal consistency reliability of the scale was evaluated using Cronbach's alpha coefficient. Additionally, latent profile analysis (LPA) and receiver operating characteristic (ROC) curve analysis were employed to determine the optimal cut-off point for the scale.

Results: The Cronbach's alpha coefficient for the CMSES was 0.92. Exploratory factor analysis revealed that the four items could be decomposed into two factors, namely magnitude and strength, which explained 76% of the total variance. Additionally, the scale demonstrated good convergent and discriminant validity. LPA identified three categories of medication self-efficacy among participating children: low (6.9%), medium (40.5%), and high (52.6%). Setting the cut-off point at 16, ROC analysis successfully distinguished children with low medication self-efficacy from others, yielding an area under the curve (AUC) of 88.5% (95% CI: 86.8%-90.2%).

Conclusion: The CMSES is an effective and reliable tool for assessing medication self-efficacy in children.

Keywords: Medication self-efficacy, children, instrument development, factor analysis, cut-off point

Ziying YU[1], Jin YU[2], Yongqiang Gao[3], Ting WANG[4], Xinyu WANG[1], Pan LIU[1], Qinghui MENG[1,*], Yibo WU[5,*]

[1] School of Nursing, Shandong Second Medical University, Weifang, China
[2] School of Psychology, Beijing Normal University, Beijing, China
[3] School of Nursing, Henan University of Science and Technology, Luoyang, China
[4] School of Nursing, Dalian University, Dalian, China
[5] School of Public Health, Peking University, Beijing, China

Introduction

Medication Self-efficacy and Adherence in Children

To ensure that medications achieve their therapeutic effects, patients need to have good medication adherence to act in accordance with the prescription. However, in reality, medication non-adherence is very common among patients with chronic diseases, with studies reported about 40% non-adherence among Chinese patient populations (Lee et al., 2013; Yue, Bin, Weilin, & Aifang, 2015), which undermines patient outcomes and increases patient mortality, threatening the effectiveness of public health investments. Therefore, it is crucial to identify and control factors that can predict medication adherence. One important predictor of medication adherence is medication self-efficacy, in other words, the patient's confidence to take the medication properly. The relationship between medication adherence and self-efficacy was validated in numerous studies, such as those focusing on diabetes(Walker, Smalls, Hernandez-Tejada, Campbell, & Egede, 2014), hypertension (Criswell, Weber, Xu, & Carter, 2010), and HIV (Barclay et al., 2007; Molassiotis et al., 2002; Wolf et al., 2007). Some interventions targeting self-efficacy also improved patient medication adherence(Appalasamy, Ramaiah, Quek, Md Zain, & Tha, 2020). Therefore, it is essential to measure and monitor patients' medication self-efficacy to manage their medication quality effectively.

For pediatric patients, medication non-adherence is an even more serious and complex issue, as children's medication requires supervision from caregivers, and children are often less tolerant of the medication-taking process due to factors like the bitter taste of drugs and difficulty swallowing (Matsui, 2007). Therefore, more efforts are needed to improve medication adherence in children. Among the various factors influencing pediatric medication adherence, self-efficacy is an important predictor (Littlefield et al., 1992; Ott, Greening, Palardy, Holderby, & DeBell, 2000). Researchers have found that children with higher self-efficacy tend to have better medication adherence. However, these studies have primarily focused on general self-efficacy, which may not specifically predict medication self-efficacy in the healthcare context. To our knowledge, there is currently no research exploring the relationship between medication self-efficacy and medication adherence in pediatric populations, which may be due to the lack of measurement tools specifically designed for assessing medication self-efficacy in children. This gap presents an obstacle to effectively monitoring and intervening in the medication practices of pediatric

patients.

The Measurement of Medication Adherence Self-Efficacy

Currently, some scales have developed to measure medication self-efficacy from various perspectives and have demonstrated acceptable reliability and validity. For example, the widely used Medication Understanding and Use Self-Efficacy Scale (Cameron et al., 2010) was originally developed for patients with chronic diseases. This scale measures two dimensions: taking medication and learning about medication, with four items for each dimension. It used a 6-point likert scale to reflect the patient's current self-efficacy in adhering to daily medication schedules and predicts long-term changes in self-efficacy based on their understanding of medication. Another prominent scale, the Self-Efficacy for Appropriate Medication Use Scale (Risser, Jacobson, & Kripalani, 2007), measures patients' confidence in adhering to their medication regimen under difficult, uncertain, or changing circumstances. This scale consists of 13 items scored on a 3-point scale and uses simplified language, making it suitable for patients with varying levels of literacy. Additionally, other scales were available for measuring medication self-efficacy in patients with specific conditions such as hypertension(Fernandez, Chaplin, Schoenthaler, & Ogedegbe, 2008) , diabetes(Sleath et al., 2016) , and HIV(Erlen, Cha, Kim, Caruthers, & Sereika, 2010) .

While these medication self-efficacy scales were well-validated across different patient populations, applying these existing scales to pediatric populations poses a challenge:The length of these scales, with at least 8 items each, makes it less likely to ensure reliability and validity when children complete them.. If efforts were made to shorten these scales, it is essential to clarify which components of the existing scales are core to the construct of self-efficacy, allowing for the retention of only the most relevant items. In fact, during the development of these widely used scales, the concept of self-efficacy was not always explicitly discussed. Despite the relatively extensive number of items in these scales, they may not fully capture the comprehensive construct of medication self-efficacy.

Self-Efficacy Dimensions

The concept of self-efficacy comes from social cognitive theory, which suggests that behavior results from the interaction between the environment and cognitive processes. A key factor influencing behavior is an individual's belief in their own abilities. Bandura (1977) argued that an individual's decision to initiate a behavior, the

amount of effort they invest in it, and the duration of their persistence in the face of unfavorable outcomes depend not only on their actual expectations of the behavior's results but also on their conviction that they can successfully execute the behavior required to achieve the desired outcomes (Bandura, 1977). This variable, known as self-efficacy, can be influenced through interventions, thereby altering individual behavior. According to this definition, self-efficacy comprises the following dimensions: magnitude, generality, and strength. Magnitude refers to the belief in one's ability to accomplish various tasks across different levels of difficulty. Generality indicates whether this capability is confined to specific situations or reflects a broader sense of confidence. Strength measures the effort one is willing to exert when faced with disconfirming experiences. To effectively assess medication self-efficacy, a scale should focus on both the magnitude and strength dimensions, omitting the generality dimension since it is specific to medication self-efficacy.

Previous medication self-efficacy scales have addressed the dimensions of magnitude and strength to varying degrees. For instance, the MUSE scale includes two factors—taking medication and learning about it—each with different magnitudes. In factor analysis, these dimensions appear as related but distinct factors, as understanding medication can be more challenging than merely following a medication schedule. In contrast, the SEAMS scale assesses various levels of medication self-efficacy strength, acknowledging that maintaining adherence demands greater effort when daily life circumstances change, such as being away from home. Currently, widely used medication self-efficacy scales do not comprehensively consider these factors to provide a complete measurement of medication self-efficacy, which has raised questions about the reliability and validity of the measurements. (Lamarche, Tejpal, & Mangin, 2018). When the measurement is limited to specific life scenarios or particular medication behaviors, the self-efficacy reflected is partial and incomplete. As a result, it is more susceptible to change when the patient's life circumstances shift, reducing its predictive power regarding actual medication adherence. Only one qualitative study(De Geest, Abraham, Gemoets, & Evers, 1994) has considered both magnitude and strength dimensions of medication self-efficacy, generating a pool of items that address different levels of these dimensions. However, the validity of this scale has not been confirmed, and even after simplification, it still contains 27 items (Denhaerynck et al., 2003), making it difficult to apply to pediatric patient populations.

The Present Study

This study aims to develop a medication self-efficacy scale tailored for children. On one hand, the scale needs to be shortened to ensure that children can complete it as required. On the other hand, it should encompass the dimensions of magnitude and strength of self-efficacy to ensure a more comprehensive and stable measurement. We synthesized the content of various existing medication self-efficacy scales and, based on expert consultations, generated a children's medication self-efficacy scale with four items that measure medication self-efficacy under different levels of magnitude and strength. We then administered the scale and used data from children's actual responses to validate its reliability and validity, thereby assessing the scale's suitability for use in pediatric populations. Based on the sample responses, we used latent profile analysis to describe the levels and distribution of medication self-efficacy among Chinese children and to determine the cutoff value for low medication self-efficacy. Through the development and validation of this scale, we hope to provide clinicians with a tool for measuring medication self-efficacy in children, enabling them to more quickly and accurately assess medication adherence and the effectiveness of clinical interventions.

2 Methods

2.1 Instrument develpoment

The first step in developing the Children's Medication Self-Efficacy Scale involved a thorough review and synthesis of existing literature to ensure that the research team had a comprehensive understanding of the concept of medication self-efficacy. Information was primarily gathered through searches of PubMed, EMBASE, ScienceDirect, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals Database (VIP), and Wanfang Data. Researchers were tasked with independently creating representative items within each dimension, resulting in a total of 10 items. Subsequently, all researchers independently evaluated the clarity, relevance to the topic, and uniqueness of the items to ensure they were clearly described and could represent either the level or intensity dimensions. Items that were consistently or predominantly recognized by the researchers were further evaluated. After merging similar items, excluding minor ones, and adding missing items, a total of 4 items were retained: 2 items for the level dimension and 2 items for the intensity dimension. A five-point Likert scale was employed, ranging from 1 (strongly disagree) to 5 (strongly agree), with higher scores indicating higher self-efficacy in medication

use among children.

2.2 Testing the validity and reliability

2.2.1 Participants

This study was conducted nationwide from May 2023 to November 2023. An electronic version of the questionnaire was created using the Wenjuanxing platform. Researchers distributed the questionnaires to participants in person, who then responded by clicking on the provided link using mobile devices such as smartphones. A total of 3,532 questionnaires were distributed, with 2,745 remaining after logical screening. Ultimately, 2,258 questionnaires were included in the final analysis. According to scholar DeVellis, if the number of items in a scale is less than or equal to 40, a sample size of 200 participants is required for a stable scale evaluation(DeVellis & Thorpe, 2021). Based on this standard, the sample of 2,258 participants in this study is highly satisfactory.

To be eligible to participate in this study, patients had to meet the following criteria: (a) considering that younger children might have difficulty completing the questionnaire and in line with the WHO definition of children, the age range was set at 8-17 years; (b) normal intellectual ability with the capability to read and write independently to complete the questionnaire; (c) voluntary participation in this study. However, patients meeting the following criterion were excluded: children with severe mental disorders.

2.2.2 Factor analysis

Exploratory factor analysis

Exploratory factor analysis (EFA) was conducted to determine the structure of the scale using IBM SPSS 27.0 software. Prior to performing the factor analysis, the Kaiser-Meyer-Olkin (KMO) test and Bartlett's test of sphericity were conducted. A KMO value greater than 0.7 and a p-value less than 0.05 from Bartlett's test of sphericity indicate that the data are suitable for factor analysis.

Relevant studies indicate that for large sample sizes and non-normally distributed data, Generalized Least Squares (GLS) is the preferred method for conducting EFA (Özvarış et al., 2022). Orthogonal rotation assumes no correlation between factors; however, this is rarely the case for research variables. Therefore, methodologists recommend using oblique rotation (Norris & Lecavalier, 2010). The 2258 data in this study were tested to be non-normally distributed and did have some correlation between the factors.Therefore, it was ultimately decided to use the GLS method to extract common factors and to apply the optimal oblique rotation method. Items with

factor loadings greater than 0.4 were retained.

Confirmatory factor analysis

Confirmatory factor analysis (CFA) was conducted to validate the structure of the scale. This study used Mplus 8.0 with the maximum likelihood method to perform CFA on the sample. The model fit was evaluated using five fit indices: χ^2/df, CFI, TLI, RMSEA, and SRMR. The criteria for a satisfactory model fit were: $\chi^2/df<3$, CFI>0.9, TLI>0.9, RMSEA<0.08, and SRMR<0.08. Meeting these criteria indicates a good model fit.

2.2.3 Concurrent validity

Criterion validity examines the correlation between the current scale and a well-established scale, with higher correlation coefficients indicating better criterion validity and greater reliability of the scale(Yi, Shin, & Shin, 2006). Criterion validity includes both concurrent validity and predictive validity, primarily differing in the time aspect.

In this study, the Short General Self-Efficacy Scale (SGSES) was selected to measure concurrent validity. The SGSES was chosen because it is a concise and reliable scale with good validity and reliability, providing great convenience for both researchers and participants. Additionally, it demonstrates flexibility and applicability within the Chinese population. The SGSES consists of three items, forming a unidimensional scale, with scores ranging from 0 to 15; higher scores indicate higher self-efficacy. The Cronbach's α coefficient of the SGSES is 0.876, and in this study, the Cronbach's α coefficient was found to be 0.956.

2.2.4 Convergent and discriminative validity

Convergent validity of the scale was evaluated using the Average Variance Extracted (AVE) and Composite Reliability (CR) indicators. Convergent validity is considered good when AVE>0.5 and CR>0.7. To assess discriminant validity, the correlations between latent variables were calculated and compared with the square root of the AVE ($\sqrt{AVE}$). Discriminant validity is confirmed when all correlation coefficients are less than their corresponding $\sqrt{AVE}$, indicating that each factor is distinct from the others.

2.2.5 Reliability

The reliability of the scale was evaluated by calculating the internal consistency of the items. Internal consistency refers to the repeatability and consistency of the scores obtained from the scale during assessment(Yuxi Liu et al., 2023). We measured the internal consistency of the scale using Cronbach's α coefficient. A Cronbach's α

coefficient above 0.8 indicates excellent reliability; above 0.7 is considered acceptable; above 0.6 suggests that the scale should be revised but still holds some value; a coefficient below 0.6 indicates that the scale needs to be redesigned(Yew, Tan, Nazan, & Manaf, 2023).

We also assessed the split-half reliability of the scale. This involved dividing the scale into two parts, which can be done either by splitting it into the first and second halves or by dividing it into odd and even items. The Pearson correlation coefficient between the scores of the two parts was then calculated. Generally, a split-half reliability coefficient above 0.8 is required.

2.3 Latent profile analysis

Unlike variable-centered statistical methods, which typically classify based on means and proportions, Latent Profile Analysis (LPA) is person-centered. In the absence of a "gold standard" for measurement tools, LPA is often used to identify cutoff values for scales(Wu et al., 2023). It employs the Latent Profile Model (LPM) to identify latent subgroups within a set of continuous variables and classifies individuals into multiple distinct profiles.

This study used Mplus 8.0 software to conduct LPA on four items of the Children's Medication Self-Efficacy Scale. Starting with one profile, models were incrementally increased and fitted and compared based on criteria such as the Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), Sample-Size Adjusted BIC (aBIC), Bootstrap Likelihood Ratio Test (BLRT), Lo–Mendell–Rubin Test (LMRT), and entropy, until the optimal model was identified(Tein, Coxe, & Cham, 2013). Lower values of AIC, BIC, and aBIC indicate a better fit, although these indicators generally decrease with an increasing number of profiles. An entropy value of ≥0.80 indicates high classification quality(Li et al., 2020). The BLRT and LMRT are used to test differences between two models (k-profile vs. k-1 profile), with $P < 0.05$ suggesting that the k- model is superior(Nylund, Asparouhov, & Muthén, 2007).

2.4 Receiver operating characteristic analysis

Receiver Operating Characteristic (ROC) analysis was conducted using SPSS 27.0. The classification performance was evaluated based on metrics such as the Area Under the ROC Curve (AUC), sensitivity, specificity, and Youden's index. An AUC value closer to 1 indicates stronger diagnostic ability. The optimal cutoff value can be determined based on Youden's index.

3 Results

3.1 Socio-demographic characteristics

A total of 3,532 questionnaires were distributed, with 2,745 remaining after logical screening,yielding a response rate of 77.72% .Ultimately, 2,258 questionnaires were included in the final analysis.Among the respondents, 48.3% were male; the majority of participants were aged 13-17 years (74.4%); a relatively higher proportion had agricultural household registrations (52.7%); the largest group of participants were primary school students (39.9%), while the smallest group were undergraduate students (1.5%)(For detailed information, see Table 1).

3.2 Reliability

The overall Cronbach's α coefficient for the scale was 0.92, with the level dimension at 0.83 and the intensity dimension at 0.88. This indicates that the scale has very high reliability and excellent internal consistency. The split-half reliability showed that the Cronbach's α for the first half of the scale was 0.83 and for the second half was 0.88, both greater than 0.8, demonstrating good split-half reliability.

3.3 Factor analysis

Exploratory factor analysis

Bartlett's test of sphericity indicated a statistically significant difference (χ^2=6540.243; P<0.001), and the Kaiser-Meyer-Olkin (KMO=0.844) measure was greater than 0.60 (see Table 2). These two tests suggest that the data are suitable for factor analysis. According to the Kolmogorov-Smirnov test, the sample showed a non-normal distribution (P<0.001), and Pearson correlations indicated correlations between factors. Based on this, we used GLS and optimal oblique rotation to extract two fixed common factors.

Items were removed based on the following criteria: factor loadings below 0.40 and high cross-loadings (loadings greater than 0.30 on two or more factors). Examination revealed that all four items had factor loadings greater than 0.40 with no cross-loadings, so all items were retained.

Table 3 presents the factor loadings for the two-factor structure: level dimension (loading range from 0.472 to 0.806) and intensity dimension (loading range from 0.530 to 0.813). Factor 1 includes items 1 and 2, representing the level dimension of medication self-efficacy; 2 includes items 3 and 4, representing the intensity dimension. These two common factors explained 76% of the total variance, which is greater than 60%.

Confirmatory factor analysis

We used the maximum likelihood method.Table 4 shows the five fit indices for the CFA: χ^2=8.059, CFI=0.999, TLI=0.995, RMSEA=0.056, and SRMR=0.003. Except for the relatively high χ^2 value, all other indices demonstrated good fit. However, this is not a major concern because a large sample size can inflate χ^2 and lead to false positive results(Liu, Zhou, Ouyang, Yang, & Xie, 2023); the sample size in this study exceeds 2,000 (see Table 4).

3.4 Concurrent validity

It shows a negative correlation between the Short General Self-Efficacy Scale and the Children's Medication Self-Efficacy Scale (r=-0.13, P<0.001). Each dimension also demonstrated a negative correlation with the total score of the Short General Self-Efficacy Scale.

3.5 Convergent and discriminative validity

The AVE values for the two factors were >0.50 (magnitude dimension=0.77; strength dimension=0.85), and the CR values were >0.70 (magnitude dimension=0.93; strength dimension=0.95), indicating good convergent validity. Additionally, $\sqrt{AVE}$ for each factor was greater than the absolute value of the correlation coefficients between the factors, demonstrating that internal correlations were greater than external correlations. This indicates that the scale has good discriminant validity (see Table 5).

3.6 Latent profile analysis

The fit indices for the five models are presented in Table 6. We observe that AIC, BIC, and aBIC decrease as the number of profiles increases. All entropy values are above 0.90. Except for the p-value of the LMR in the 5-Profile model, which is greater than 0.05, the p-values for the LMR and BLRT in the other profiles are statistically significant. Considering both model fit and the practical context of this study, the 3-Profile model is ultimately selected as the best model for the current sample.

The distribution of scale items in the 3-Profile model is shown in Figure 1. Class 1, comprising 6.9% of the sample (n=151), is defined as the "Low Self-Efficacy" group. Class 2, including 40.5% of the sample (n=931), is defined as the "Moderate Self-Efficacy" group. Class 3, representing 52.6% of the sample (n=1176), is defined as the "High Self-Efficacy" group. The average latent class probabilities for most likely latent class membership (0.952, 0.974, and 0.980, respectively) indicate that the model's classification is reasonable and shows good discriminative ability (see Table

7).

3.7 Receiver operating characteristic analysis

Based on the results of the LPA, individuals classified into the "Low Self-Efficacy" group are defined as "cases," while individuals in the "Moderate Self-Efficacy" and "High Self-Efficacy" groups are defined as "non-cases"(Fu, Si, & Guo, 2022)。 Using this binary classification, we plotted the ROC curve for CMSES. The AUC value is 88.5% (95% CI: 86.8%-90.2%), indicating excellent predictive ability for children's self-efficacy (see Figure 2). Table 8 presents the diagnostic indicators for the latent cutoff values, with the optimal cutoff value for CMSES being 16, corresponding to the highest Youden index (0.867), sensitivity of 0.867, and specificity of 1.

Discussion

This study developed and validated a brief and efficient medication self-efficacy scale specifically designed for children. The content of the scale is based on Bandura's self-efficacy theory and includes four items that cover the magnitude and strength dimensions of self-efficacy. This allows for the quick screening and assessment of children's confidence in taking medication and using it correctly in various situations. The scale demonstrated good reliability and validity, making it useful for predicting children's medication adherence and evaluating the effectiveness of medication interventions in pediatric patients with chronic illnesses.

Unlike previous studies on the development of medication self-efficacy scales, this research is grounded in a clear theoretical framework and provides a well-defined conceptualization of medication self-efficacy. We propose that medication self-efficacy should encompass the magnitude and strength dimensions of self-efficacy, i.e., the child's confidence in handling medication tasks of varying difficulty under different life circumstances. We selected two representative items for each dimension based on expert recommendations: for the magnitude dimension, we included tasks of varying difficulty, specifically "taking medication on time" and "remembering all correct methods of medication use." For the strength dimension, we aimed to measure the patient's perceived effort in adhering to medication when capacity is limited, choosing the items "changes in medication methods" and "busy lifestyle." By selecting these four items, we aim to comprehensively cover the two dimensions of medication self-efficacy, thereby achieving a more accurate and stable measurement of medication self-efficacy. This, in turn, enhances the predictive power

of this construct in relation to medication adherence.

To validate the psychometric properties of the scale in pediatric patients, we collected data from 2,258 children. These samples ranged in age from 8 to 17 years and included a diverse representation of gender and educational backgrounds, ensuring both diversity and representativeness. Internal consistency reliability analysis was conducted based on these data, revealing that the overall scale (Cronbach's α=0.92) and both subscales (Cronbach's α>0.83) demonstrated excellent Cronbach's alpha coefficients. This indicates that the items within the scale consistently measure the intended constructs.

For the validation of construct validity, during the development of the scale, we aimed for the four items to represent the two dimensions of self-efficacy. Factor analysis revealed that items 1 and 2, as well as items 3 and 4, were explained by two distinct factors, aligning with our expectations. The Average Variance Extracted (AVE) values showed that the internal correlations of these two factors were greater than their external correlations, indicating good discriminant validity among the different items of the scale. We believe that these two reduced factors represent the magnitude and strength dimensions of medication self-efficacy, respectively. This scale provides a comprehensive measurement of the different dimensions of medication self-efficacy, which is beneficial as it allows for a more accurate reflection of the structure of medication self-efficacy. The magnitude dimension represents the difficulty level of the medication task, where correctly remembering all medication instructions is more challenging than merely taking the medication on time. As the number of medications increases, the complexity of the task also increases, potentially leading to a decrease in medication adherence (Knight et al., 2001). Therefore, starting a medication regimen does not necessarily mean that the child can take the correct dosage (Menditto et al., 2021); using two items helps capture the child's performance across both simple and difficult medication tasks. The strength dimension of medication adherence reflects the effort the patient invests in taking their medication. Maintaining proper medication adherence requires more resources when daily life is busy or when there are changes in medication methods (Lehane & McCarthy, 2007). In these situations, self-efficacy levels might be lower than usual, as patients may feel that daily life consumes much of their energy, reducing the cognitive resources available to remember to take their medication, and thus decreasing their confidence in taking it correctly. This scale's measurement covers these two dimensions, providing a more

comprehensive reflection of medication self-efficacy, which in turn leads to better stability and accuracy.

However, when we examined the relationship between medication self-efficacy and general self-efficacy, an unexpected result emerged. Correlation analysis revealed that the total score for medication self-efficacy and its sub-dimensions were negatively correlated with general self-efficacy. This finding suggests that self-efficacy has varying degrees of specificity, and general self-efficacy may not necessarily be effective in the context of medication adherence. Patients with high medication self-efficacy may not necessarily have high levels of general self-efficacy across other domains. One possible explanation for this negative correlation is that children with high medication self-efficacy might have more severe health conditions, leading to lower general self-efficacy. The specific mechanisms underlying this relationship require further investigation and validation.

To determine the distribution of medication self-efficacy among Chinese pediatric patients, we conducted a latent profile analysis of the sample's responses using this scale. The results indicate that the level of medication self-efficacy among the participants can be categorized into three groups: most participants had high (52.6%) or moderate (40.5%) self-efficacy, while 6.9% had low self-efficacy. We believe that this latter group should be the primary focus of healthcare professionals for intervention. Therefore, a cutoff value needs to be established to identify these individuals. To balance the specificity and sensitivity of the scale, we performed a receiver operating characteristic (ROC) analysis, which showed that a cutoff value of 15.5 yielded the highest Youden's index, best distinguishing those with low medication self-efficacy. Thus, the cutoff value for this scale is set at 15: participants scoring greater than or equal to 15 are considered to have potentially low medication self-efficacy and should undergo further evaluation and intervention.

Implications

On one hand, the scale can be used for the rapid screening of medication self-efficacy in pediatric patients. Clinicians often need to assess a child's medication adherence, but measuring adherence can be challenging and typically requires observation over a period of medication use. In such cases, assessing the patient's medication self-efficacy can serve as a predictive indicator of adherence, helping to identify children who may have poor adherence and require further intervention. On the other hand, this scale can also be used as an outcome measure for interventions

aimed at improving medication adherence in children. When an increase in a child's medication self-efficacy is observed, it can be anticipated that their medication adherence will likely improve as well.

Limitations

First, the scale examines general medication self-efficacy without distinguishing between specific conditions, medication duration, frequency, or quantity. Longer disease courses, higher medication quantities, and fluctuating frequencies can increase the difficulty of medication adherence potentially reducing patients' adherence and their self-efficacy in managing their medication. Future research could validate the scale's applicability across different pediatric conditions. Second, this scale includes representative scenarios to reflect different strength and magnitude of medication self-efficacy. However, the item descriptions are based on experience and expert recommendations, so it remains to be verified whether they effectively measure children's medication self-efficacy levels. Third, like many studies on the development of medication self-efficacy scales, this research only measured self-efficacy at a single cross-sectional time point, without examining whether this measurement can predict long-term medication adherence. Longitudinal validation is needed to enhance the reliability of the scale.

References

Appalasamy, J. R., Ramaiah, S. S., Quek, K. F., Md Zain, A. Z., & Tha, K. K. (2020). Medication Understanding and Taking Self-Efficacy Theory-Based Interventions. Journal of Young Pharmacists, 12(1), 18-24. doi:10.5530/jyp.2020.12.5

Bandura, A. (1977). Self-efficacy: toward a unifying theory of behavioral change. Psychological review, 84(2), 191.

Barclay, T. R., Hinkin, C. H., Castellon, S. A., Mason, K. I., Reinhard, M. J., Marion, S. D., . . . Durvasula, R. S. (2007). Age-associated predictors of medication adherence in HIV-positive adults: Health beliefs, self-efficacy, and neurocognitive status. Health Psychology, 26(1), 40-49. doi:10.1037/0278-6133.26.1.40

Cameron, K. A., Ross, E. L., Clayman, M. L., Bergeron, A. R., Federman, A. D., Bailey, S. C., . . . Wolf, M. S. (2010). Measuring patients' self-efficacy in understanding and using prescription medication. Patient Education and Counseling, 80(3), 372-376. doi:10.1016/j.pec.2010.06.029

Criswell, T. J., Weber, C. A., Xu, Y., & Carter, B. L. (2010). Effect of self‐efficacy and social support on adherence to antihypertensive drugs. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 30(5), 432-441.

De Geest, S., Abraham, I., Gemoets, H., & Evers, G. (1994). Development of the long - term medication behaviour self - efficacy scale: qualitative study for item development. Journal of advanced nursing, 19(2), 233-238.

Denhaerynck, K., Abraham, I., Gourley, G., Drent, G., De Vleeschouwer, P., Papajcik, D., . . . De Geest, S. (2003). Validity testing of the long-term medication behavior self-efficacy scale. Journal of nursing measurement, 11(3), 267-282.

DeVellis, R. F., & Thorpe, C. T. (2021). Scale development: Theory and applications: Sage publications.

Erlen, J. A., Cha, E. S., Kim, K. H., Caruthers, D., & Sereika, S. M. (2010). The HIV Medication Taking Self - efficacy Scale: Psychometric evaluation. Journal of advanced nursing, 66(11), 2560-2572.

Fernandez, S., Chaplin, W., Schoenthaler, A. M., & Ogedegbe, G. (2008). Revision and validation of the medication adherence self-efficacy scale (MASES) in hypertensive African Americans. Journal of behavioral medicine, 31, 453-462.

Fu, H., Si, L., & Guo, R. (2022). What is the optimal cut-off point of the 10-item Center for Epidemiologic Studies Depression Scale for screening depression among Chinese individuals aged 45 and over? An exploration using latent profile analysis. Frontiers in psychiatry, 13, 820777.

Lamarche, L., Tejpal, A., & Mangin, D. (2018). Self-efficacy for medication management: a systematic review of instruments. Patient preference and adherence, 1279-1287.

Lee, G. K., Wang, H. H., Liu, K. Q., Cheung, Y., Morisky, D. E., & Wong, M. C. (2013). Determinants of medication adherence to antihypertensive medications among a Chinese population using Morisky Medication Adherence Scale. PLoS One, 8(4), e62775.

Li, J.-B., Wu, A. M., Feng, L.-F., Deng, Y., Li, J.-H., Chen, Y.-X., . . . Lau, J. T. (2020). Classification of probable online social networking addiction: A latent profile analysis from a large-scale survey among Chinese adolescents. Journal of Behavioral Addictions, 9(3), 698-708.

Littlefield, C. H., Craven, J. L., Rodin, G. M., Daneman, D., Murray, M. A., & Rydall, A. C. (1992). Relationship of self-efficacy and binging to adherence to diabetes regimen among adolescents. Diabetes care, 15(1), 90-94.

Liu, Y., Zhang, J., Xue, H., Chen, M., Xie, T., & Wan, C. (2023). Development and validation of the systemic lupus erythematous scale amongst the system of quality of life instruments for chronic diseases QLICD-SLE (V2. 0). Health and Quality of Life Outcomes, 21(1), 128.

Liu, Y., Zhou, B., Ouyang, Y., Yang, B., & Xie, Q. (2023). Development and validation of Chinese form short dark tetrad (C-SD4). Heliyon, 9(1).

Matsui, D. (2007). Current issues in pediatric medication adherence. Pediatric Drugs, 9, 283-288.

Molassiotis, A., Nahas-Lopez, V., Chung, W. R., Lam, S. C., Li, C. P., & Lau, T. J. (2002). Factors associated with adherence to antiretroviral medication in

HIV-infected patients. International journal of STD & AIDS, 13(5), 301-310.

Norris, M., & Lecavalier, L. (2010). Evaluating the use of exploratory factor analysis in developmental disability psychological research. Journal of autism and developmental disorders, 40, 8-20.

Nylund, K. L., Asparouhov, T., & Muthén, B. O. (2007). Deciding on the number of classes in latent class analysis and growth mixture modeling: A Monte Carlo simulation study. Structural equation modeling: a multidisciplinary journal, 14(4), 535-569.

Ott, J., Greening, L., Palardy, N., Holderby, A., & DeBell, W. K. (2000). Self-efficacy as a mediator variable for adolescents' adherence to treatment for insulin-dependent diabetes mellitus. Children's Health Care, 29(1), 47-63.

Özvarış, Ş. B., Doğan, B. G., Ünlü, H. K., Karadag, O., Doğan, N., Gelbal, S., & Sakarya, S. (2022). Development and Validation of a Culture-Sensitive Generic Health Literacy Scale in Turkish-Speaking Adults. HLRP: Health Literacy Research and Practice, 6(1), e2-e11.

Risser, J., Jacobson, T. A., & Kripalani, S. (2007). Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. Journal of nursing measurement, 15(3), 203-219.

Sleath, B., Carpenter, D. M., Blalock, S. J., Davis, S. A., Hickson, R. P., Lee, C., . . . Cummings, D. M. (2016). Development of a new diabetes medication self-efficacy scale and its association with both reported problems in using diabetes medications and self-reported adherence. Patient preference and adherence, 1003-1010.

Tein, J.-Y., Coxe, S., & Cham, H. (2013). Statistical power to detect the correct number of classes in latent profile analysis. Structural equation modeling: a multidisciplinary journal, 20(4), 640-657.

Walker, R. J., Smalls, B. L., Hernandez-Tejada, M. A., Campbell, J. A., & Egede, L. E. (2014). Effect of diabetes self-efficacy on glycemic control, medication adherence, self-care behaviors, and quality of life in a predominantly low-income, minority population. Ethnicity & disease, 24(3), 349.

Wolf, M. S., Davis, T. C., Osborn, C. Y., Skripkauskas, S., Bennett, C. L., & Makoul, G. (2007). Literacy, self-efficacy, and HIV medication adherence. Patient Education and Counseling, 65(2), 253-260.

Wu, Y., Dai, Z., Xiao, W., Wang, H., Huang, Y., Si, M., . . . Leng, Z. (2023). Perceived stigma among discharged patients of COVID-19 in Wuhan, China: A latent profile analysis. Frontiers in Public Health, 11, 1111900.

Yew, S.-Q., Tan, K.-A., Nazan, A. I. N. M., & Manaf, R. A. (2023). Development and validation of a medication non-adherence scale for Malaysian hypertensive patients: a mixed-methods study. Environmental Health and Preventive Medicine, 28, 75-75.

Yi, H., Shin, K., & Shin, C. (2006). Development of the sleep quality scale. Journal of sleep research, 15(3), 309-316.

Yue, Z., Bin, W., Weilin, Q., & Aifang, Y. (2015). Effect of medication adherence on

blood pressure control and risk factors for antihypertensive medication adherence. Journal of evaluation in clinical practice, 21(1), 166-172.

Table1　General Characteristics of Participants(N=2258)

Variables	Category	Mean ± SD or n (%)
Age (years)		14.04±2.49
Gender	Male	1091（48.3）
	Female	1167（51.7）
Household registration type	Non-agricultural	1068（47.3）
	Agriculture	1190（52.7）
Education level	Primary school	902（39.9）
	Secondary school	585（25.9）
	High school degree	236（10.5）
	Technical secondary school education	463（20.5）
	Associate degree	38（1.7）
	Bachelor degree	34（1.5）

Table2　KMO and Bartlett's Test (N=2258)

Kaiser–Meyer–Olkin measure of sampling adequacy	0.844
Bartlett's test of sphericity	
Approx. chi-square	6540.243
df	6
Sig	0.000

N=2258.df=Degrees of freedom

Table3　Rotated Factor Loadings for the scale(N=2258)

Items	Factor1	Factor2
1.It's easy for me to take medicine on time every day	0.472	
2.It's easy for me to remember the correct way to take all my medications	0.806	
3.When my medication changed, I was able to take it on time		0.425
4.When I am busy with school work, I can also take my medicine on time		0.079

Table4　Model fit of the scale(N=2258)

Goodness of Fit	χ^2 （p）	df	χ^2/df	CFI	TLI	RMSEA	SRMR
Results	8.059	1	8.059	0.999	0.995	0.056	0.003

χ^2 = chi-square，df = degrees of freedom，CFI = comparative fit index,TLI = Tucker–Lewis index, RMSEA = root mean square error of approximation,SRMR=standardized root mean square residual .

Table5   Convergent and discriminative validity(N=2258)

	AVE	CR	Factor 1	Factor 2
Factor 1	0.774	0.928	0.870[a]	
Factor 2	0.847	0.955	0.832[b]	0.920[a]

Factor1 =magnitude dimension , Factor2 =strength dimension
AVE, average variance extracted; CR, composite reliability.
a Square root of AVE.
b Absolute value of the correlation coefficient between factors.

Table 6   Model fit indices for one- to five-latent prrofile solutions

Class number	AIC	BIC	aBIC	pLMR p-value	pBLRT p-value	Entropy
1	27675.206	27675.206	27695.566			
2	22627.754	22702.143	22660.84	<0.001	<0.001	0.925
3	20605.858	20708.858	20651.669	<0.001	<0.001	0.928
4	18608.177	18739.789	18666.714	0.0013	<0.001	0.959
5	17826.67	17986.892	17897.932	0.3071	<0.001	0.996

Table7 Average latent profile probabilities for most likely latent profile membership (row) by latent profile (column).

Latent class	Latent class membership		
	1 (151)	2 (931)	3 (1176)
1	0.952	0.010	0.039
2	0.026	0.974	0. 000
3	0.020	0.000	0.980

The columns refer to latent profile, and the rows refer to most likely profile membership. Profile 1 = low medication self-efficacy; Profile 2 = moderate medication self-efficacy; Profile 3 = high medication self-efficacy.

Table8 Criterion values and coordinates of ROC Curve for medication self-efficacy.

Criterion	Sensitivity	Specificity	Youden's index
12.5	0.886	0.69	0.576
13.5	0.886	0.777	0.663
14.5	0.886	0.899	0.785
15.5*	**0.867***	**1***	**0.867***
16.5	0.569	1	0.569
17.5	0.509	1	0.509
18.5	0.446	1	0.446

Figure 1 Latent Profle indicators mean values for the three-profle solution.

Figure 2 The ROC curve of the the CMSES for screening Medication Self-Efficacy.